Searched for
GLAXO
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- GSK's Calpol a well-known trademark: High CourtThe Delhi High Court has recognized GlaxoSmithKline Pharmaceuticals' pain and fever medicine, Calpol, as a well-known trademark. This desig...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Bombay HC backs GSK in Paxil trademark row against Shreya Life SciencesThe Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medici...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%It is tough to think positively about the markets when all the news is about blockades, wars, and everything that can disturb the global ec...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%The official kickoff of the Q4 earnings season happens when a large IT company announces its results, although the quarter’s business updat...
- CCI approves Corona Remedies-GlaxoSmithKline dealDilo-BM, Dilo-DX, Stelbid and Vitneurin brands of GlaxoSmithKline would be acquired by Corona Remedies along with trademark and goodwill.
- Buy Glaxo SmithKline with a target of Rs 2750: Mitesh Thacker'Glaxo SmithKline is a 'BUY' call with a target of Rs 2750 and a stop loss of Rs 2620.'
- GlaxoSmithKline Consumer Healthcare Ltd India-Novartis deal won't affect business in IndiaGlaxoSmithKline Consumer Healthcare today said the global deal between GlaxoSmithKline Plc and Novartis won't affect its business in India.
- NSE to drop GlaxoSmithKline Consumer from F&O segmentNSE said it will exclude GlaxoSmithKline Consumer Healthcare from the Futures and Options segment with effect from May 30.
- GlaxoSmithKline Plc's open offer for GSKCH to start on January 17The UK-based GlaxoSmithKline Plc's open offer to acquire 31.8 per cent stake in its Indian subsidiary GlaxoSmithKline Consumer Healthcare w...
- Buy GlaxoSmithKline Pharmaceuticals with a target of 2350: Ashwani GujralGlaxoSmithKline Pharmaceuticals Ltd is a ‘BUY’ call with a target of Rs 2350 and a stop loss of Rs 2200.
- Positive on Sesa Goa and GlaxoSmithKline: Ashwani GujralSesa Goa remains quite range bound between say levels of about 290 to about 345-350 and GlaxoSmithKline, the volumes are low.
- Glaxo takes new AIDS drug into final-stage testsGlaxoSmithKline and its partner Shionogi are progressing a new drug against HIV into final-stage clinical testing, ramping up competition i...
- Glaxo bets India, China focus will help take on rivalsGlaxoSmithkline plans to double revenue from India and China by 2015 as the drugmaker cuts prices to catch up with Pfizer, Sanofi-Aventis a...
Load More
